Gedeon Richter

Gedeon Richter Plc. is a Hungarian pharmaceutical and biotechnology company headquartered in Budapest. Founded in 1901 by pharmacist Gedeon Richter, it developed from a small pharmacy-based laboratory into one of Central and Eastern Europe's largest pharmaceutical businesses. The company researches, manufactures, licenses and distributes medicines across a broad international network, with direct commercial or operating activity in Europe, Asia, North America and Latin America and products available in more than 100 countries. Richter's early work reflected the scientific direction of the pharmaceutical industry at the beginning of the twentieth century. Its first products were organotherapeutic preparations made from animal-organ extracts, followed by herbal medicines, plant extracts and synthetic compounds. A manufacturing plant built in Budapest's Kőbánya district in 1907 gave the company industrial-scale capacity and helped establish Hungary as a pharmaceutical production base. Richter later became known for products including lecithin preparations, antiseptics, acetylsalicylic-acid medicines and adrenaline-related products. Its international distribution network also expanded early; in the 1930s, Constant Janssen obtained distribution rights for Richter products, linking the company to the business network that later became associated with Janssen Pharmaceuticals. The company was nationalized in 1948 and remained state-owned for several decades. During the 1970s, its researchers developed vinpocetine, a compound marketed from 1977 under the brand Cavinton for cerebrovascular indications. The product became one of Richter's best-known innovations and demonstrated the company's ability to combine domestic research with international commercialization. After Hungary's economic transition, Richter was privatized in stages and returned to private ownership in 1994. Today, Richter's research and commercial portfolio spans women's health, neuroscience, biosimilars, oncology and cardiovascular medicine, among other fields. Women's health has been strengthened through internal research and acquisitions, including the 2010 purchase of Swiss biopharmaceutical company PregLem, which focused on gynecological conditions and infertility. In neuroscience, cariprazine, marketed as Reagila in relevant markets, became an important proprietary product for schizophrenia and bipolar disorder. The company also develops and commercializes biosimilars and maintains partnerships for development, manufacturing, licensing and distribution. Richter operates manufacturing and research facilities in Budapest, Dorog and Debrecen, as well as international subsidiaries and joint ventures. Its business model combines proprietary drug discovery, generic and specialty pharmaceuticals, contract or partner manufacturing, biosimilar development and regional distribution. The company has maintained a primary listing on the Budapest Stock Exchange and has also had a secondary listing in Luxembourg. Its strategic identity is that of a research-led European pharmaceutical group with particular strength in specialty therapies and international partnerships rather than a consumer-health brand.

Gedeon Richter was established in Budapest in 1901 when pharmacist Gedeon Richter obtained a license to manufacture medicines industrially. Production initially took place on a small scale in the Arany Sas, or Golden Eagle, Pharmacy. The business worked with extracts from animal organs and developed organotherapeutic preparations, reflecting the medical manufacturing practices of the period. In 1907, Richter opened an industrial plant in the Kőbánya district of Budapest. It was Hungary's first pharmaceutical factory and gave the company a platform for larger-scale production. The portfolio broadened from organ extracts to herbal preparations, plant-based products and synthetic medicines. Richter became associated with lecithin products, the antiseptic Hyperol, aspirin-related brands and adrenaline products. International distribution also developed before the Second World War; in 1934, Constant Janssen acquired distribution rights for Richter medicines. The company was nationalized in 1948 and operated as a state-owned enterprise for much of the socialist period. Its research organization continued to develop medicines, and in the 1970s company chemists discovered vinpocetine. Introduced in 1977 as Cavinton, the product became a major commercial success in treatments associated with cerebrovascular disorders and established Richter's reputation for original pharmaceutical research. Following Hungary's transition toward a market economy, Richter was privatized in stages and returned to private ownership in 1994. The company subsequently combined its domestic research and manufacturing base with international subsidiaries, licensing arrangements and strategic partnerships. One controversial episode occurred in the 1990s, when Richter contracted with Danco Laboratories concerning US commercialization of mifepristone. Richter withdrew from the effort in 1997 amid opposition from US pro-life groups, and Danco brought a lawsuit alleging contractual and financial harm. During the 2000s and 2010s, Richter expanded its manufacturing and specialty-pharmaceutical capabilities. It signed agreements involving Proellex and terbinafine, built a biotechnology facility in Debrecen, and acquired Swiss company PregLem in 2010. PregLem added capabilities and products in gynecology and infertility. Richter also expanded biosimilar activities, including a European distribution agreement with Stada for pegfilgrastim. The company's women's-health strategy continued through agreements with Evestra, Pantarhei Bioscience and Mithra Pharmaceuticals. Its neuroscience portfolio gained international importance through cariprazine, marketed as Reagila, which is used for schizophrenia and bipolar disorder in approved markets. The product received Hungarian innovation recognition and a Medicine of the Year award. More recently, Richter has pursued research collaborations in neuropsychiatry, including agreements with AbbVie involving dopamine-receptor modulators. Richter's operating structure includes its Budapest headquarters and manufacturing sites in Dorog and Debrecen, together with subsidiaries and joint ventures in Europe, India and the Americas. The company remains listed on the Budapest Stock Exchange and presents itself as a research-oriented pharmaceutical group with activities in innovative medicines, biosimilars, generic and specialty products, manufacturing and international commercialization.

1. 2017Cariprazine innovation recognition

   The Hungarian Innovation Foundation recognized Richter's development of cariprazine.

   Source
2. 2012Debrecen biotechnology facility begins operation

   A new biotechnology and manufacturing site in Debrecen became operational.

   Source
3. 2010PregLem acquisition

   Richter acquired the Swiss biopharmaceutical company PregLem, expanding its women's-health and infertility activities.

   Source
4. 1994Return to private ownership

   Richter completed its transition from state ownership to a privatized corporate structure.

   Source
5. 1977Cavinton introduced

   Richter commercialized vinpocetine under the Cavinton brand.

   Source
6. 1948Nationalization

   The company became state-owned and remained so until the post-socialist privatization process.

   Source
7. 1934International distribution agreement

   Constant Janssen acquired distribution rights for Richter products.

   Source
8. 1907Kőbánya industrial plant opens

   Richter opened Hungary's first pharmaceutical manufacturing plant in Budapest's Kőbánya district.

   Source
9. 1901Company founded in Budapest

   Pharmacist Gedeon Richter received an industrial medicine-production license and began pharmaceutical manufacturing.

   Source

Research-driven European pharmaceutical and biotechnology company with strong capabilities in women's health, neuroscience, biosimilars and specialty medicines.

• ReagilaNeuroscience

  Reagila is Richter's brand for cariprazine, an atypical antipsychotic used in approved markets for schizophrenia and bipolar disorder. It is one of the company's principal proprietary neuroscience products and a major example of Richter's strategy of developing differentiated prescription medicines rather than relying solely on commoditized generics.

• CavintonCerebrovascular medicine1977

  Cavinton is the brand associated with vinpocetine, a compound discovered by Richter researchers in the 1970s and introduced in 1977. It became one of the company's best-known historical products and was marketed for cerebrovascular indications, including conditions associated with impaired cerebral circulation.

• Contraceptive portfolioWomen's health

  Richter maintains a broad women's-health business covering oral contraceptives and other gynecological products. The portfolio has been supported by internal development, licensing and supply agreements, and partnerships with companies including Pantarhei Bioscience and Mithra Pharmaceuticals.

• Biosimilar pegfilgrastimBiosimilars2015

  Richter developed a biosimilar version of pegfilgrastim and entered a 2015 European distribution arrangement with Stada. The agreement gave Stada non-exclusive distribution rights in geographical Europe excluding Russia, while Richter retained broader commercialization rights.

• HyperolAntiseptic

  Hyperol is an antiseptic product associated with Richter's early twentieth-century manufacturing history. It illustrates the company's initial expansion from organotherapeutic preparations into branded chemical and medicinal products.

• 2006IUPAC–Richter Prize in Medicinal Chemistry

  Global

  Richter provided funding to establish the IUPAC–Richter Prize in Medicinal Chemistry, awarded biennially to an internationally recognized scientist whose work has advanced medicinal chemistry.

  Outcome. The prize created a continuing scientific-recognition program linked to pharmaceutical research.

  Source

• 2022AbbVie neuropsychiatry collaborationStrategy

  Richter and AbbVie identified an opportunity to develop new dopamine-receptor modulators for neuropsychiatric diseases.

  What changed. The companies entered an agreement to develop and commercialize novel modulators.

  Aftermath. The collaboration extended Richter's neuroscience strategy through a global pharmaceutical partnership.

  Source
• 2018Estelle commercialization collaborationStrategy

  Mithra Pharmaceuticals was developing the Estelle contraceptive and sought regional commercialization support.

  What changed. Richter began collaborating with Mithra to distribute Estelle in Europe and Russia.

  Aftermath. The agreement reinforced Richter's role as a regional women's-health commercialization partner.

  Source
• 2017Chief executive successionOther

  Erik Bogsch had led Richter as chief executive since 1992 and was moving to the board chairmanship.

  What changed. Gábor Orbán was appointed chief executive, while Bogsch became chairman after William de Gelsey left that position.

  Aftermath. The change preserved continuity while separating the chief executive and board-chair roles.

  Source
• 2015European biosimilar distribution agreementStrategy

  Richter sought broader commercialization reach for its biosimilar pegfilgrastim.

  What changed. The company granted Stada non-exclusive distribution rights in geographical Europe excluding Russia.

  Aftermath. Richter retained worldwide marketing and distribution rights outside the defined arrangement while using Stada's regional commercial network.

  Source
• 2012Expansion of biotechnology manufacturingStrategy

  Richter invested in additional production capacity to support biotechnology and specialty pharmaceutical activities.

  What changed. The company brought a new biotechnology facility in Debrecen into operation.

  Aftermath. Debrecen became one of Richter's principal manufacturing locations alongside Budapest and Dorog.

  Source
• 2010Acquisition of PregLemM&A

  Richter sought to strengthen its women's-health and gynecology activities, including treatments related to infertility.

  What changed. Richter acquired the Swiss biopharmaceutical company PregLem.

  Aftermath. The transaction expanded Richter's specialty women's-health platform and international product pipeline.

  Source
• 1997Withdrawal from planned US mifepristone commercializationStrategy

  Richter had entered an arrangement with Danco Laboratories to support US commercialization of mifepristone, a politically contested medicine.

  What changed. The company discontinued its efforts to place the product on the US market.

  Aftermath. Danco filed a lawsuit alleging breach of contract and substantial losses. The episode remains a notable example of the regulatory and political risks surrounding pharmaceutical commercialization.

  Source

• 1997Mifepristone distribution disputeControversy

  Richter ended its effort to distribute mifepristone in the United States after facing strong opposition from pro-life groups. Danco Laboratories sued Richter, alleging breach of contract and losses connected with the withdrawal.

  Source

• 2024AbbVie and Richter announce further neuropsychiatric collaboration

  The companies announced a subsequent collaboration concerning novel treatments for neuropsychiatric diseases.

  Other
  Source
• 2022AbbVie and Richter expand collaboration in neuropsychiatric disease

  AbbVie and Richter announced an agreement to develop and commercialize novel dopamine-receptor modulators for neuropsychiatric conditions.

  Other
  Source
• 2019Richter and Pantarhei Bioscience sign contraceptive agreement

  The companies agreed to license and supply a novel combined oral contraceptive for commercialization.

  Product launchOther
  Source
• 2019Reagila receives Hungarian Medicine of the Year recognition

  The Hungarian Society for Experimental and Clinical Pharmacology named Richter's cariprazine product Reagila Medicine of the Year.

  Other
  Source
• 2018Richter begins European and Russian distribution collaboration for Estelle

  Richter began collaborating with Mithra Pharmaceuticals to distribute the Estelle contraceptive in Europe and Russia.

  Other
  Source
• 2017Richter changes chief executive leadership

  Erik Bogsch became chairman after William de Gelsey stepped down, and Gábor Orbán succeeded Bogsch as chief executive later that year.

  Leadership change
  Source
• 2017Richter receives Hungarian Innovation Grand Prize for cariprazine

  The Hungarian Innovation Foundation recognized the development of cariprazine, the active ingredient in Richter's antipsychotic product Reagila.

  Other
  Source
• 2017Richter and Evestra enter collaboration partnership

  Evestra and Richter announced a collaboration involving women's-health pharmaceutical development.

  Other
  Source
• 2015Richter and Stada establish European biosimilar distribution arrangement

  Stada received non-exclusive rights to distribute Richter's biosimilar pegfilgrastim in geographical Europe outside Russia, while Richter retained broader worldwide rights.

  Other
  Source
• 2012Richter completes major Debrecen manufacturing investment

  A new biotechnology and manufacturing facility in Debrecen entered operation after a construction program that began in 2008.

  Other
  Source
• 2010Richter acquires PregLem

  Richter acquired all outstanding ownership interests in Swiss biopharmaceutical company PregLem, strengthening its gynecology and infertility business.

  M&A
  Source
• 2007Gedeon Richter agrees to manufacture terbinafine for Barr

  Richter signed a manufacturing and distribution-related agreement with Barr Pharmaceuticals concerning terbinafine for the US market.

  Other
  Source
• 2006Gedeon Richter signs Proellex development and supply agreement

  The company entered a development and supply agreement with Repros Therapeutics for Proellex.

  Other
  Source

1. Gedeon Richter (company)
2. Gedeon Richter official website
3. AbbVie and Gedeon Richter neuropsychiatry collaboration
4. AbbVie与Richter宣布进一步神经精神合作